These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 31639020)

  • 41. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
    Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
    Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
    Kanzawa T; Bedwell J; Kondo Y; Kondo S; Germano IM
    J Neurosurg; 2003 Dec; 99(6):1047-52. PubMed ID: 14705733
    [TBL] [Abstract][Full Text] [Related]  

  • 43. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system.
    Caporali S; Falcinelli S; Starace G; Russo MT; Bonmassar E; Jiricny J; D'Atri S
    Mol Pharmacol; 2004 Sep; 66(3):478-91. PubMed ID: 15322239
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines.
    Combs SE; Bohl J; Elsasser T; Weber KJ; Schulz-Ertner D; Debus J; Weyrather WK
    Int J Radiat Biol; 2009 Feb; 85(2):126-37. PubMed ID: 19280465
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
    Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J
    J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line.
    Montaldi AP; Godoy PR; Sakamoto-Hojo ET
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():19-29. PubMed ID: 26520369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multifaceted resistance of gliomas to temozolomide.
    Bocangel DB; Finkelstein S; Schold SC; Bhakat KK; Mitra S; Kokkinakis DM
    Clin Cancer Res; 2002 Aug; 8(8):2725-34. PubMed ID: 12171906
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Carnosine increases efficiency of temozolomide and irradiation treatment of isocitrate dehydrogenase-wildtype glioblastoma cells in culture.
    Dietterle J; Oppermann H; Glasow A; Neumann K; Meixensberger J; Gaunitz F
    Future Oncol; 2019 Nov; 15(32):3683-3691. PubMed ID: 31664860
    [No Abstract]   [Full Text] [Related]  

  • 50. Differential effects of radiation fractionation regimens on glioblastoma.
    McKelvey KJ; Hudson AL; Donaghy H; Stoner SP; Wheeler HR; Diakos CI; Howell VM
    Radiat Oncol; 2022 Jan; 17(1):17. PubMed ID: 35073960
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
    Kim GW; Lee DH; Yeon SK; Jeon YH; Yoo J; Lee SW; Kwon SH
    Anticancer Res; 2019 Dec; 39(12):6731-6741. PubMed ID: 31810938
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
    Garnier D; Meehan B; Kislinger T; Daniel P; Sinha A; Abdulkarim B; Nakano I; Rak J
    Neuro Oncol; 2018 Jan; 20(2):236-248. PubMed ID: 29016925
    [TBL] [Abstract][Full Text] [Related]  

  • 53. pH as a potential therapeutic target to improve temozolomide antitumor efficacy : A mechanistic modeling study.
    Stéphanou A; Ballesta A
    Pharmacol Res Perspect; 2019 Feb; 7(1):e00454. PubMed ID: 30705757
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of Cyclin D1 Expression in Human Glioblastoma Cells is Associated with Increased Temozolomide Chemosensitivity.
    Zhang D; Dai D; Zhou M; Li Z; Wang C; Lu Y; Li Y; Wang J
    Cell Physiol Biochem; 2018; 51(6):2496-2508. PubMed ID: 30562739
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
    Festuccia C; Mancini A; Colapietro A; Gravina GL; Vitale F; Marampon F; Delle Monache S; Pompili S; Cristiano L; Vetuschi A; Tombolini V; Chen Y; Mehrling T
    J Hematol Oncol; 2018 Feb; 11(1):32. PubMed ID: 29486795
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic Perspective of Temozolomide Resistance in Glioblastoma Treatment.
    Xia Q; Liu L; Li Y; Zhang P; Han D; Dong L
    Cancer Invest; 2021 Sep; 39(8):627-644. PubMed ID: 34254870
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
    Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
    Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Error-Prone DNA Polymerase κ Promotes Temozolomide Resistance in Glioblastoma through Rad17-Dependent Activation of ATR-Chk1 Signaling.
    Peng C; Chen Z; Wang S; Wang HW; Qiu W; Zhao L; Xu R; Luo H; Chen Y; Chen D; You Y; Liu N; Wang H
    Cancer Res; 2016 Apr; 76(8):2340-53. PubMed ID: 26960975
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets.
    Chien CH; Chuang JY; Yang ST; Yang WB; Chen PY; Hsu TI; Huang CY; Lo WL; Yang KY; Liu MS; Chu JM; Chung PH; Liu JJ; Chou SW; Chen SH; Chang KY
    J Biomed Sci; 2019 Oct; 26(1):77. PubMed ID: 31629402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.